Naso-oropharyngeal Brucella Infections and Mucosal Immune Protection
Naso-oropharyngeal Brucella Infections and Mucosal Immune Protection
批准号:
9751725
负责人:
David W Pascual
金额:
$37.71万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-17 至 2022-07-31
关键词:
AerosolsAffectAnimalsAntibiotic TherapyArthritisAttenuatedBrucellaBrucella abortusBrucella melitensisBrucellosisCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCervical lymph node groupClinicalConsumptionContractsCoupledDNADairy ProductsDataDetectionDiseaseEndocarditisFDA approvedGTP-Binding Protein alpha Subunits, GsGoalsHumanImmuneImmune systemImmunityImmunizationIncidenceInduced AbortionInfectionIngestionInterferon Type IIJointsLearningLifeLinkLiverLivestockLung infectionsLymph Node of Head, Face and NeckLymphoid TissueMemoryMethodsMilkMorbidity - disease rateMucous MembraneNeurologicNoseOralOral cavityOral mucous membrane structureOropharyngealOutcomePathogenesisPharyngitisPrimary InfectionProcessQuality of lifeRegimenResolutionRoleRouteRuralSiteSocioeconomic StatusSpleenSymptomsSystemic diseaseSystemic infectionT cell responseT-LymphocyteT-Lymphocyte SubsetsTNF geneTestingTextTissuesVaccinationVaccinesVirulentWorkZoonosescell typedesignflugastrointestinal symptomhuman diseaseimprovedlymph nodesmutantneglectnoveloral infectionpathogenic bacteriapersistent symptompreventresponsesocioeconomicstoolunpasteurized
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Human brucellosis ranks third among 8 neglected zoonotic diseases, and is contracted as a result of ingesting
unpasteurized dairy products. The Gram-negative Brucella is highly infectious, and is believed that less than 2000
CFUs are needed for pulmonary infection. Infection primarily occurs following a mucosal exposure causing a
systemic disease manifested by its flu-like symptoms. Despite aggressive antibiotic treatment, it can still persist
in a recurring sequelae evident as undulant fever and arthritis. Brucellae survival within the host is linked to its
ability to evade intracellular recognition, thus, allowing them to sequester in various tissues. Although human
disease is mostly acquired via a mucosal exposure, few studies have examined mucosal immunization for
brucellosis. In part, this is attributed to the inefficiency of oral gavage methods requiring an enormous amount
of brucellae to induce an infection. Bearing this, we have devised an oral infection method, termed ad bibitum,
that retains the infection to the oral mucosa and draining head and neck lymph nodes (HNLNs) recapitulating
natural human infections. Hence, we hypothesize that mucosal immunization of the naso-oropharyngeal tissues
will derive the required correlates of protective immunity using our novel attenuated Brucella melitensis (BM) strain.
Such approaches will allow for the comparison of which immune cell types are needed for protection and to
reverse wild-type (wt) BM infection from mounting regulatory responses in order to evade detection. Subsequent
to immunization, the attenuated BM mutant stimulates increases in IFN-g- and TNF-a-producing CD4+ and CD8+
T cells, which can effectively eliminate the brucellae. To further these studies, three Specific Aims are proposed.
Studies in Specific Aim 1 will establish a mucosal naso-oropharyngeal vaccination regimen that confers protection
against mucosal challenge with virulent Brucella. Studies in Specific Aim 2 will determine which T cell subsets are
responsible for protection in the mucosal and systemic compartments. Studies in Specific Aim 3 will establish the
role for mucosal memory CD8+ T cells in augmenting protection against virulent Brucella challenge more effectively
than CD4+ T cells. These studies will further our understanding of how to induce immunity in the naso-
oropharyngeal mucosa, and will aid in devising strategies to circumvent BM' evasion methods. This work will
ultimately define what constitutes protection and which T cells are needed to guard against wt BM challenges.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Snodgrassella alvi as an attenuated live vaccine against Neisseria gonorrhoeae
-
批准号:10263891
-
项目类别:
-
资助金额:$24.19万
-
财政年份:2020
-
负责人:David W Pascual
-
依托单位:
Regulatory Cell Therapy for Sjogrens Syndrome
-
批准号:10898203
-
项目类别:
-
资助金额:$35.08万
-
财政年份:2017
-
负责人:David W Pascual
-
依托单位:
Naso-oropharyngeal Brucella Infections and Mucosal Immune Protection
-
批准号:10213597
-
项目类别:
-
资助金额:$37.67万
-
财政年份:2017
-
负责人:David W Pascual
-
依托单位:
Naso-oropharyngeal Brucella Infections and Mucosal Immune Protection
-
批准号:9977090
-
项目类别:
-
资助金额:$37.69万
-
财政年份:2017
-
负责人:David W Pascual
-
依托单位:
Sony Cell Sorter SH800 System
-
批准号:9075724
-
项目类别:
-
资助金额:$29.56万
-
财政年份:2016
-
负责人:David W Pascual
-
依托单位:
Mucosal Vaccines for Brucellosis
-
批准号:9079710
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2016
-
负责人:David W Pascual
-
依托单位:
Fimbriae Countermeasures for Type 1 Diabetes
-
批准号:9242580
-
项目类别:
-
资助金额:$18.18万
-
财政年份:2016
-
负责人:David W Pascual
-
依托单位:
"Subunit Vaccines for Brucella Pathogens"
-
批准号:8651868
-
项目类别:
-
资助金额:$46.36万
-
财政年份:2011
-
负责人:David W Pascual
-
依托单位:
"Subunit Vaccines for Brucella Pathogens"
-
批准号:8827663
-
项目类别:
-
资助金额:$36.34万
-
财政年份:2011
-
负责人:David W Pascual
-
依托单位:
"Subunit Vaccines for Brucella Pathogens"
-
批准号:8076096
-
项目类别:
-
资助金额:$51.55万
-
财政年份:2011
-
负责人:David W Pascual
-
依托单位:
MT VET COBRE II CORE C: ANIMAL MODELS
-
批准号:8360160
-
项目类别:
-
资助金额:$12.63万
-
财政年份:2011
-
负责人:David W Pascual
-
依托单位:
"Subunit Vaccines for Brucella Pathogens"
-
批准号:8460570
-
项目类别:
-
资助金额:$44.4万
-
财政年份:2011
-
负责人:David W Pascual
-
依托单位:
"Subunit Vaccines for Brucella Pathogens"
-
批准号:8262375
-
项目类别:
-
资助金额:$12.43万
-
财政年份:2011
-
负责人:David W Pascual
-
依托单位:
"Subunit Vaccines for Brucella Pathogens"
-
批准号:8580995
-
项目类别:
-
资助金额:$27.72万
-
财政年份:2011
-
负责人:David W Pascual
-
依托单位:
"Mechanisms of IL-35 Protection Against Arthritis"
-
批准号:8124930
-
项目类别:
-
资助金额:$16.0万
-
财政年份:2010
-
负责人:David W Pascual
-
依托单位:
MT VET COBRE II CORE C: ANIMAL MODELS
-
批准号:8168414
-
项目类别:
-
资助金额:$14.41万
-
财政年份:2010
-
负责人:David W Pascual
-
依托单位:
"Mechanisms of IL-35 Protection Against Arthritis"
-
批准号:7917759
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2010
-
负责人:David W Pascual
-
依托单位:
Mucosal Therapy for Autoimmunity
-
批准号:8220951
-
项目类别:
-
资助金额:$16.53万
-
财政年份:2009
-
负责人:David W Pascual
-
依托单位:
Mucosal Therapy for Autoimmunity
-
批准号:7675115
-
项目类别:
-
资助金额:$17.81万
-
财政年份:2009
-
负责人:David W Pascual
-
依托单位:
DNA Vaccines for Q fever
-
批准号:7675560
-
项目类别:
-
资助金额:$18.81万
-
财政年份:2009
-
负责人:David W Pascual
-
依托单位:
海外基金